Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ)
CNY 13.74
(1.63%)
CNY 13.74
(1.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 5.88 Billion CNY | -30.08% |
| 2022 | 7.99 Billion CNY | 24.18% |
| 2021 | 6.43 Billion CNY | 13.63% |
| 2020 | 5.66 Billion CNY | 52.3% |
| 2019 | 3.71 Billion CNY | 16.82% |
| 2018 | 3.18 Billion CNY | 14.63% |
| 2017 | 2.77 Billion CNY | 9.67% |
| 2016 | 2.53 Billion CNY | 25.35% |
| 2015 | 2.02 Billion CNY | 9.59% |
| 2014 | 1.84 Billion CNY | 11.08% |
| 2013 | 1.65 Billion CNY | 47.57% |
| 2012 | 1.12 Billion CNY | -15.79% |
| 2011 | 1.33 Billion CNY | 22.01% |
| 2010 | 1.09 Billion CNY | 9.95% |
| 2009 | 995.52 Million CNY | 78.15% |
| 2008 | 558.82 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 920.83 Million CNY | -14.35% |
| 2024 Q1 | 1.25 Billion CNY | 107.16% |
| 2024 Q2 | 1.07 Billion CNY | -14.28% |
| 2023 Q3 | 1.03 Billion CNY | -36.46% |
| 2023 Q4 | 605.44 Million CNY | -41.75% |
| 2023 Q1 | 2.55 Billion CNY | -16.54% |
| 2023 Q2 | 1.63 Billion CNY | -36.0% |
| 2023 FY | 5.58 Billion CNY | -30.08% |
| 2022 Q3 | 1.46 Billion CNY | -18.81% |
| 2022 Q2 | 1.8 Billion CNY | 8.59% |
| 2022 Q1 | 1.66 Billion CNY | 35.27% |
| 2022 Q4 | 3.06 Billion CNY | 109.16% |
| 2022 FY | 7.99 Billion CNY | 24.18% |
| 2021 FY | 6.43 Billion CNY | 13.63% |
| 2021 Q1 | 2.35 Billion CNY | 42.59% |
| 2021 Q2 | 1.45 Billion CNY | -38.12% |
| 2021 Q3 | 1.39 Billion CNY | -4.59% |
| 2021 Q4 | 1.22 Billion CNY | -11.77% |
| 2020 Q3 | 1.22 Billion CNY | -4.32% |
| 2020 Q4 | 1.65 Billion CNY | 35.45% |
| 2020 FY | 5.66 Billion CNY | 52.3% |
| 2020 Q1 | 1.51 Billion CNY | 82.73% |
| 2020 Q2 | 1.27 Billion CNY | -15.78% |
| 2019 Q3 | 882.08 Million CNY | -11.99% |
| 2019 Q1 | 1 Billion CNY | 55.9% |
| 2019 Q2 | 1 Billion CNY | -0.35% |
| 2019 Q4 | 828.88 Million CNY | -6.03% |
| 2019 FY | 3.71 Billion CNY | 16.82% |
| 2018 Q3 | 739.51 Million CNY | 2.61% |
| 2018 FY | 3.18 Billion CNY | 14.63% |
| 2018 Q1 | 1.07 Billion CNY | 58.17% |
| 2018 Q2 | 720.67 Million CNY | -33.17% |
| 2018 Q4 | 645.16 Million CNY | -12.76% |
| 2017 Q1 | 895.14 Million CNY | 52.76% |
| 2017 Q3 | 567.41 Million CNY | -10.36% |
| 2017 FY | 2.77 Billion CNY | 9.67% |
| 2017 Q4 | 681.79 Million CNY | 20.16% |
| 2017 Q2 | 632.99 Million CNY | -29.29% |
| 2016 FY | 2.53 Billion CNY | 25.35% |
| 2016 Q1 | 744.96 Million CNY | 65.65% |
| 2016 Q2 | 639.75 Million CNY | -14.12% |
| 2016 Q3 | 561.75 Million CNY | -12.19% |
| 2016 Q4 | 585.99 Million CNY | 4.32% |
| 2015 Q1 | 549.52 Million CNY | 31.48% |
| 2015 Q4 | 449.72 Million CNY | -7.81% |
| 2015 Q3 | 487.8 Million CNY | -8.53% |
| 2015 Q2 | 533.28 Million CNY | -2.96% |
| 2015 FY | 2.02 Billion CNY | 9.59% |
| 2014 Q4 | 417.94 Million CNY | -2.17% |
| 2014 FY | 1.84 Billion CNY | 11.08% |
| 2014 Q2 | 476.44 Million CNY | -8.71% |
| 2014 Q1 | 521.89 Million CNY | 20.4% |
| 2014 Q3 | 427.22 Million CNY | -10.33% |
| 2013 Q4 | 433.47 Million CNY | 1.16% |
| 2013 FY | 1.65 Billion CNY | 47.57% |
| 2013 Q1 | 404.14 Million CNY | 1.26% |
| 2013 Q2 | 393.52 Million CNY | -2.63% |
| 2013 Q3 | 428.5 Million CNY | 8.89% |
| 2012 FY | 1.12 Billion CNY | -15.79% |
| 2012 Q1 | 304.32 Million CNY | -23.64% |
| 2012 Q2 | 175.85 Million CNY | -42.22% |
| 2012 Q3 | 245.34 Million CNY | 39.52% |
| 2012 Q4 | 399.1 Million CNY | 62.67% |
| 2011 Q1 | 273.1 Million CNY | -30.56% |
| 2011 Q2 | 320.69 Million CNY | 17.43% |
| 2011 Q3 | 343.16 Million CNY | 7.01% |
| 2011 Q4 | 398.55 Million CNY | 16.14% |
| 2011 FY | 1.33 Billion CNY | 22.01% |
| 2010 Q3 | 258.34 Million CNY | 0.0% |
| 2010 Q4 | 393.29 Million CNY | 52.24% |
| 2010 FY | 1.09 Billion CNY | 9.95% |
| 2009 FY | 995.52 Million CNY | 78.15% |
| 2008 FY | 558.82 Million CNY | 0.0% |